15 October 2021
EMA/PDCO/521274/2021
Human Medicines Division

Paediatric Committee (PDCO)

Minutes for the meeting on 7-10 September 2021

Chair: Koenraad Norga – Vice-Chair: Sabine Scherer

Disclaimers

Some of the information contained in this set of minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued).

Of note, this set of minutes is a working document primarily designed for PDCO members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introductions

1.1. Welcome and declarations of interest of members, alternates and experts

The Chairperson opened the meeting by welcoming all participants. Due to the current coronavirus (COVID-19) outbreak, and the associated EMA Business Continuity Plan (BCP), the meeting was held remotely.

In accordance with the Agency's policy on handling of declarations of interests of scientific Committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of some meeting participants in upcoming discussions as included in the pre-meeting list of participants and restrictions.

Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members (i.e. 17 or more members were present in the room). All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

Due to restricted involvement, the Chair Koenraad Norga deputised chairing the meeting to the Vice-Chair Sabine Scherer for the agenda topic(s) 2.1.17, 2.1.43, 3.1.52, 3.1.53 and 3.3.21.

1.2. Adoption of agenda

The agenda for 7-10 September 2021 meeting was adopted.

1.3. Adoption of the minutes

The minutes for 20-23 July 2021 meeting were adopted and will be published on the EMA website.

2. Opinions

Some information related to this section cannot be disclosed at the present time as it is deemed to contain commercially confidential information.

2.1. Opinions on Products

2.1.1. AZD8233 sodium, PCSK9-targeted, antisense oligonucleotide (ASO) - EMEA-002962-PIP01-21

AstraZeneca AB; Treatment of elevated cholesterol / Treatment of mixed dyslipidaemia

Day 120 opinion

Cardiovascular Diseases

Summary of Committee discussion:

Taking into account additional information received between Day 90 and Day 120, the PDCO adopted a positive opinion on this PIP for the condition "treatment of elevated cholesterol", for patients from 6 years of age with heterozygous familial hypercholesterolaemia (HeFH) or homozygous familial hypercholesterolaemia (HoFH). A waiver was agreed for the condition "treatment of elevated cholesterol" for the paediatric population from birth to less than 6 years of age on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments. Moreover, a waiver for the whole paediatric population from birth to less than 18 years of age was granted for the condition "treatment of mixed dyslipidaemia" on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2.1.2. 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid tris(hydroxymethyl)aminomethane salt (1:1) - EMEA-002944-PIP01-20

Pfizer Europe MA EEIG; Treatment of type 2 diabetes mellitus

Day 120 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of Committee discussion:

All requests made by the PDCO at Day 90 could be resolved with the applicant.
Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agreed on a PIP with a deferral for PF-06882961, as well as a waiver in children from birth to less than 10 years of age in the condition, treatment of type 2 diabetes mellitus, on the grounds that the condition for which the product is intended does not occur in this age range.

2.1.3. Drospirenone - EMEA-001495-PIP02-21

Chemo Research, S.L.; Treatment of endometriosis

Day 120 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO

recommends granting a waiver for drospirenone for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of endometriosis on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in boys from birth to less than 18 years of age and girls from birth to menarche, and on the grounds that the specific medicinal product does not represent a significant therapeutic for all girls from menarche to less than 18 years of age.

2.1.4. Glepaglutide - EMEA-002926-PIP01-20

Zealand Pharma A/S; Treatment of short bowel syndrome

Day 120 opinion

Gastroenterology-Hepatology

Summary of Committee discussion:

Based on the assessment of this application and the additional information provided by the applicant, a positive opinion for the PIP for the proposed medicine for children from 4 months to less than 18 years of age, in the condition of treatment of short bowel syndrome was adopted. The PDCO agreed on a waiver in a subset of children from birth to less than 4 months of age on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s). The PDCO granted a deferral for the completion of this PIP.

2.1.5. Semaglutide - EMEA-001441-PIP05-20

Novo Nordisk A/S; Treatment of non-alcoholic steatohepatitis

Day 120 opinion

Gastroenterology-Hepatology

Summary of Committee discussion:

Based on the assessment of this application and the additional information provided by the applicant, a positive opinion for the PIP for the proposed medicine for children and adolescents from 8 years to less than 18 years of age, in the condition treatment of non-alcoholic steatohepatitis. The PDCO agreed on a waiver in a subset of children from birth to less than 8 years of age on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments. The PDCO granted a deferral for the completion of this PIP.

2.1.6. Adalimumab conjugated with (4S)-4-[2-(2-bromoacetamido)acetamido]-5-{3-[(4-{(4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)-5-hydroxy-4a,6a-dimethyl-2-oxo-6b-[(phosphonooxy)acetyl]-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H,8H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-8-yl}phenyl)methyl] anilino}-5-oxopentanoic acid; (ABBV-154) - EMEA-002927-PIP01-20

AbbVie Ltd; Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis)

Day 120 opinion

Immunology-Rheumatology-Transplantation

Summary of Committee discussion:

Taking into account information submitted between Day 90 and Day 120 the PDCO adopted a positive opinion on this PIP for the condition "treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis)". A waiver was agreed for the paediatric population from birth to less than 1 year of age on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset and for the paediatric population from 1 year to less than 2 years of age on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2.1.7. Islatravir - EMEA-002938-PIP01-20

Merck Sharp & Dohme (Europe), Inc.; Prevention of human immunodeficiency virus (HIV-1) infection

Day 120 opinion

Infectious Diseases

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agreed on a PIP and a waiver in children from birth to less than 12 years of age on grounds of a lack of significant therapeutic benefit in the condition of prevention of human immunodeficiency virus (HIV-1) infection.

2.1.8. Pritelivir (mesylate monohydrate) - EMEA-002180-PIP02-19

AiCuris Anti-infective Cures AG; Treatment of herpes simplex virus disease

Day 120 opinion

Infectious Diseases

Summary of Committee discussion:

Based on the assessment of this application and the additional information provided by the applicant with some additions in the opinion, a positive opinion for the PIP for the proposed medicine for the age subset from 6 years to less than 18 years of in the condition of treatment of herpes simplex virus disease was adopted.
The PDCO agreed on a waiver for the subset of children from birth to less than 6 years of age on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s) and granted a deferral for the completion of this PIP.

2.1.9. Propan-2-yl (2S)-2-{[(S)-({(2R,3R,4R,5R)-5-[2-amino-6-(methylamino)-9H-purin-9-yl]-4-fluoro-3-hydroxy-4-methyloxolan-2-yl}methoxy)(phenoxy)phosphoryl]amino}propanoate; sulfuric acid (2:1) (AT-527 / RO7496998) - EMEA-002963-PIP01-21

Roche Registration GmbH; Treatment of coronavirus disease 2019 (COVID-19)

Day 120 opinion

Infectious Diseases

Summary of Committee discussion:

In September 2021 the PDCO noted that all remaining issues were resolved during a consultation on a draft opinion with the applicant.

The PDCO agreed with the applicant's request for a PIP for RO7496998 (AT-527) with a deferral in the condition of treatment of coronavirus disease 2019 (COVID-19).

2.1.10. Terbinafine hydrochloride - EMEA-002984-PIP01-21

Moberg Pharma AB; Treatment of onychomycosis

Day 120 opinion

Infectious Diseases

Summary of Committee discussion:

The PDCO discussed in September 2021 the responses of the applicant to the D90 discussion. The PDCO agreed a PIP for terbinafine hydrochloride for the treatment of onychomycosis with a deferral and a waiver for the paediatric population from birth to less than 6 years on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible.

2.1.11. Crisantaspase - EMEA-002934-PIP01-20

Jazz Pharmaceuticals Ireland Ltd.; Treatment of acute lymphoblastic leukaemia / lymphoma

Day 120 opinion

Oncology

Summary of Committee discussion:

Based on the assessment of this application and the additional information provided by the applicant after the D90 discussion, a positive opinion for the PIP for the proposed medicine for the entire population in the condition of treatment of acute lymphoblastic leukaemia and treatment of lymphoblastic lymphoma was adopted. The PDCO granted a deferral for the completion of this PIP.

2.1.12. Loncastuximab tesirine - EMEA-002665-PIP02-20

ADC Therapeutics SA; Treatment of mature B cell neoplasms

Day 120 opinion

Oncology

Summary of Committee discussion:

The PDCO re-discussed at Day 120, during the September 2021 plenary meeting, a PIP application for loncastuximab tesirine, and antibody-drug conjugate directed against CD19 for the treatment of mature B cell neoplasms.
Taking into account this and previous discussions, the PDCO adopted a positive opinion on a paediatric investigation plan with a deferral for loncastuximab tesirine for the treatment of mature B cell neoplasms and a waiver for children from birth to less than 6 months of age on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for this paediatric subset.

2.1.13. Brensocatib - EMEA-002905-PIP01-20

Insmed Netherlands B.V.; Treatment of non-cystic fibrosis bronchiectasis

Day 120 opinion

Pneumology - Allergology

Summary of Committee discussion:

In the written response, the applicant addressed the remaining issues raised by the Committee. Based on the assessment of this application and the additional information provided by the applicant, a positive opinion for the PIP for the proposed medicine for children from 6 years to less than 18 years in the condition of treatment of non-cystic fibrosis bronchiectasis was adopted.

2.1.14. Thienopyrimidine derivative - EMEA-002901-PIP01-20

Boehringer Ingelheim International GmbH; Treatment of fibrosing interstitial lung disease

Day 120 opinion

Pneumology - Allergology

Summary of Committee discussion:

In the written response, the applicant addressed the remaining issues raised by the Committee.
Based on the assessment of this application and the additional information provided by the applicant, a positive opinion for the PIP for the proposed medicine for the paediatric population from 2 years to less than 18 years of age, in the condition of 'treatment of fibrosing interstitial lung diseases' was adopted. The PDCO agreed on a waiver in a subset of children (from birth to less than 2 years of age) based on the grounds that the specific medicinal product is likely to be unsafe. The PDCO granted a deferral for the completion of this PIP.

2.1.15. Ravulizumab - EMEA-001943-PIP02-20

Alexion Europe SAS; Treatment in haematopoietic stem cell transplantation

Day 120 opinion

Uro-nephrology / Haematology-Hemostaseology

Summary of Committee discussion:

The PDCO adopted a positive opinion on this PIP for the condition "treatment in haematopoietic stem cell transplantation". A waiver was agreed for the paediatric population from birth to less than 28 days of age on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset.

2.1.16. Live-attenuated La Reunion strain of chikungunya virus (VLA1553) - EMEA-002873-PIP01-20

Valneva Austria GmbH; Active immunisation for the prevention of disease caused by chikungunya virus

Day 120 opinion

Vaccines

Summary of Committee discussion:

The PDCO discussed this procedure on D120. The applicant's responses to the D90 issues were in general considered acceptable except from the number of participants for study 5 (from birth to less 1 year of age).
A positive opinion for the PIP for the proposed medicine for the paediatric population from birth to less than 18 years of age in the condition of prevention of chikungunya disease was adopted on D120.
The PDCO granted a deferral for the completion of this PIP.

2.1.17. Respiratory syncytial virus (RSV) PreF3 recombinant fusion protein - EMEA-002904-PIP01-20

GlaxoSmithKline Biologicals SA; Prevention of lower respiratory tract disease caused by respiratory syncytial virus

Day 120 opinion

Vaccines

Summary of Committee discussion:

The PDCO discussed the responses of the applicant.

The PDCO adopted a positive opinion on this PIP for respiratory syncytial virus (RSV) PreF3 recombinant fusion protein for prevention of lower respiratory tract disease caused by RSV.

2.1.18. Zofenopril (calcium) / amlodipine - EMEA-003036-PIP01-21

Menarini Ricerche S.p.A.; Treatment of hypertension

Day 60 opinion

Cardiovascular Diseases

Summary of Committee discussion:

The PDCO confirmed the outcome of Day 30 discussion and based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant´s request for a waiver. The PDCO recommends granting a waiver for zofenopril (calcium) / amlodipine for all subsets of the paediatric population (from birth to less than 18 years of age) for the condition of treatment of hypertension, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2.1.19. Ezetimibe / rosuvastatin - EMEA-001447-PIP02-21

Egis Pharmaceuticals PLC; Prevention of cardiovascular events

Day 60 opinion

Cardiovascular Diseases

Summary of Committee discussion:

The Committee adopted a positive opinion on granting a product-specific waiver for all subsets of the paediatric population the above mentioned condition in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

2.1.20. Ezetimibe / rosuvastatin - EMEA-003018-PIP01-21

Qualipharmacon Kft.; Treatment of hypercholesterolemia / Prevention of cardiovascular events

Day 60 opinion

Cardiovascular Diseases

Summary of Committee discussion:

The PDCO granted a waiver for rosuvastatin / ezetimibe for all subsets of the paediatric population (0 to 18 years of age) in the conditions prevention of cardiovascular events and treatment of hypercholesterolaemia.

2.1.21. Ezetimibe / rosuvastatin - EMEA-003039-PIP01-21

Sandoz s.r.o.; Prevention of cardiovascular events / Treatment of hypercholesterolemia

Day 60 opinion

Cardiovascular Diseases

Summary of Committee discussion:

The PDCO granted a waiver for rosuvastatin / ezetimibe for all subsets of the paediatric population (0 to 18 years of age) in the conditions Prevention of cardiovascular events and treatment of hypercholesterolaemia.

2.1.22. Manganese chloride - EMEA-003035-PIP01-21

Diagnostic evaluation of liver lesions by magnetic resonance imaging

Day 60 opinion

Diagnostic / Oncology

Note: Withdrawal request received on 7 September 2021

2.1.23. Perflubutane - EMEA-003037-PIP01-21

GE Healthcare AS; Diagnostic evaluation of focal hepatic lesions

Day 60 opinion

Diagnostic / Oncology

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agreed to refuse the granting of a product-specific waiver for perflubutane for all subsets of the paediatric population (0 to 18 years of age) in the condition of diagnostic evaluation of focal hepatic lesions as it does not meet the grounds detailed in Article 11(1) of said Regulation.

2.1.24. Pyridoxine (hydrochloride) / doxylamine (succinate) - EMEA-001608-PIP02-21

EXELTIS HEALTHCARE S.L.; Treatment of nausea and vomiting of pregnancy

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of Committee discussion:

Based on the assessment of this application and discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for the proposed medicine (as prolonged-release tablet) for all subsets of the paediatric population from birth to less than 18 years of age for the condition 'treatment of nausea and vomiting of pregnancy' on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2.1.25. Rusfertide - Orphan - EMEA-003045-PIP01-21

Protagonist Therapeutics, Inc.; Treatment of polycythaemia vera

Day 60 opinion

Haematology-Hemostaseology

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO

recommends granting a waiver for rusfertide for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of polycythaemia vera on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need.

2.1.26. Tocilizumab - EMEA-000309-PIP06-21

Roche Registration GmbH; Treatment of systemic sclerosis

Day 60 opinion

Immunology-Rheumatology-Transplantation

Summary of Committee discussion:

Based on the assessment of this application and further discussions, the PDCO agreed on a recommendation to refuse the granting of a product-specific waiver for all subsets of the paediatric population (from birth to less than 18 years of age) in the condition of treatment of systemic sclerosis as it does not meet the grounds detailed in Article 11(1) of said Regulation.

2.1.27. Anti-C1s humanized IgG4 monoclonal antibody - EMEA-002903-PIP03-21

Genzyme Europe B.V.; Treatment of chronic inflammatory demyelinating polyradiculoneuropathy

Day 60 opinion

Immunology-Rheumatology-Transplantation / Haematology-Hemostaseology / Neurology

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for anti-C1s humanized IgG4 monoclonal antibody for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of chronic inflammatory demyelinating polyradiculoneuropathy based on the ground that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible.

2.1.28. Anti-neonatal Fc receptor human monoclonal antibody - EMEA-002559-PIP04-21

Janssen-Cilag International NV; Treatment of chronic inflammatory demyelinating polyradiculoneuropathy

Day 60 opinion

Neurology

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for anti-neonatal Fc receptor human monoclonal antibody for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of chronic inflammatory demyelinating polyradiculoneuropathy based on the ground that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible for the age group of children from 2 to less than 18 years of age and on the grounds that the specific medicinal product is likely to be unsafe in children from birth to less than 2 years of age.

2.1.29. Efgartigimod alfa - EMEA-002597-PIP06-21

argenx BV; Treatment of chronic inflammatory demyelinating polyradiculoneuropathy

Day 60 opinion

Neurology

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for efgartigimod alfa for all subsets of the paediatric population (0 to 18 years of age) in the condition of chronic inflammatory demyelinating polyradiculoneuropathy based on the ground that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible for the age group of children from 2 to less than 18 years of age and on the grounds that the specific medicinal product is likely to be unsafe in children from birth to less than 2 years of age.

2.1.30. Izaflortaucipir (^{18}F) - Orphan - EMEA-003040-PIP01-21

Life Molecular Imaging GmbH; Diagnosis of corticobasal degeneration / Diagnosis of progressive supranuclear palsy

Day 60 opinion

Neurology

Summary of Committee discussion:

Based on the assessment of this application, the PDCO agrees with the applicant's waiver requests. The PDCO recommends granting a waiver for izaflortaucipir (^{18}F) for all subsets of the paediatric population (birth to less than 18 years of age) in the conditions of diagnosis of progressive supranuclear palsy (PSP) and diagnosis of corticobasal degeneration (CBD) on the grounds that the conditions only occur in adults.

2.1.31. Ravulizumab - EMEA-001943-PIP05-21

Alexion Europe SAS; Treatment of amyotrophic lateral sclerosis

Day 60 opinion

Neurology

Summary of Committee discussion:

Based on the assessment of this application the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for the proposed product for ravulizumab for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of amyotrophic lateral sclerosis on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible.

The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from generating as much data in the paediatric population as possible, as there might be paediatric patients, who could derive benefit from this kind of product.

2.1.32. 5'-capped mRNA encoding HPV16 oncoprotein E6 and E7 - EMEA-003023-PIP01-21

BioNTech SE; Treatment of head and neck squamous cell carcinoma

Day 60 opinion

Oncology

Summary of Committee discussion:

In the written response the applicant addressed the remaining issues raised by the Committee. Based on the assessment of this application and discussions at the Paediatric Committee the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for the proposed medicine for all subsets of the paediatric population from birth to less than 18 years of age for the condition of treatment of head and neck squamous cell carcinoma on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subsets. The PDCO recommended to grant the waiver for all pharmaceutical forms and all routes of administration to which the applicant agreed.

The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.33. Alnuctamab - EMEA-003046-PIP01-21

Bristol-Myers Squibb International Corporation; Treatment of mature B cell malignancies

Day 60 opinion

Oncology

Summary of Committee discussion:

Based on the assessment of this application and discussions at the Paediatric Committee the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for the proposed medicine for all subsets of the paediatric population from birth to less than 18 years of age for the condition of treatment of mature B cell malignancies on

the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.34. Anti-CD123 IgG1 humanised monoclonal antibody conjugated to N1-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)-N6-((S)-1-(((S)-1-((3-((((S)-8-methoxy-6-oxo-11,12,12a,13-tetrahydro-6H-benzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)methyl)-5-((((S)-8-methoxy-6-oxo-12a,13-dihydro-6Hbenzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)methyl)phenyl)amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)adipamide - Orphan - EMEA-003044-PIP01-21

Immunogen BioPharma (Ireland) Limited; Treatment of blastic plasmacytoid dendritic cell neoplasm

Day 60 opinion

Oncology

Summary of Committee discussion:

Based on the assessment of this application and discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for anti-CD123 IgG1 humanised monoclonal antibody conjugated to N1-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)-N6-((S)-1-(((S)-1-((3-((((S)-8-methoxy-6-oxo-11,12,12a,13-tetrahydro-6H-benzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)methyl)-5-((((S)-8-methoxy-6-oxo-12a,13-dihydro-6Hbenzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)methyl)phenyl)amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)adipamide for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of blastic plasmacytoid dendritic cell neoplasm, on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset.
The PDCO recommended to grant the waiver for all pharmaceutical forms and all routes of administration to which the applicant agreed.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need.

2.1.35. B cell maturation antigen antibody-drug conjugate comprised of an immunoglobulin G1 humanized antibody conjugated covalently to the dibenzocyclooctyne noncleavable linker maytansinoid warhead (BMS-986352) - EMEA-003047-PIP01-21

Bristol-Myers Squibb International Corporation; Treatment of mature B cell neoplasms

Day 60 opinion

Oncology

Summary of Committee discussion:

The PDCO re-discussed at Day 60, during the September 2021 plenary meeting, an application for a product-specific waiver for B cell maturation antigen antibody-drug conjugate comprised of an immunoglobulin G1 humanized antibody conjugated covalently to the dibenzocyclooctyne noncleavable linker maytansinoid warhead (BMS-986352).
The PDCO confirmed all conclusions reached at Day 30 and adopted a positive opinion on a product specific waiver for this product for all subsets of the paediatric population (from birth to less than 18 years of age) in the condition of "treatment of mature B cell neoplasms" on the grounds that the product is not expected to be of significant therapeutic benefit because clinical studies would not be feasible.

2.1.36. Batiraxcept - EMEA-003042-PIP01-21

Aravive, Inc; Treatment of primary peritoneal cancer / Treatment of fallopian tube cancer / Treatment of ovarian cancer

Day 60 opinion

Oncology

Summary of Committee discussion:

In the written response, the applicant addressed the remaining issues raised by the Committee.
Based on the assessment of this application and discussions at the Paediatric Committee the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for the proposed medicine for all subsets of the paediatric population from birth to less than 18 years of age for the conditions treatment of ovarian cancer, treatment of fallopian tube cancer and treatment of primary peritoneal cancer on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subsets.

2.1.37. Pralsetinib - EMEA-002575-PIP03-21

Roche Registration GmbH; Treatment of all conditions included in the category of malignant neoplasms [except lung cancer (small cell and non-small cell cancer), thyroid neoplasms, central nervous system tumours, haematopoietic and lymphoid tissue neoplasms] / Treatment of malignant neoplasms of haematopoietic and lymphoid tissue / Treatment of malignant neoplasms of the central nervous system

Day 60 opinion

Oncology

Summary of Committee discussion:

The PDCO re-discussed at day 60, during the September 2021 plenary meeting, an application for a product-specific waiver for pralsetinib, a RET inhibitor for the treatment of all conditions included in the category of malignant neoplasms (except thyroid neoplasms) based on lack of significant therapeutic benefit.
The PDCO adopted a positive opinion on a product specific waiver for pralsetinib for all subsets of the paediatric population (from birth to less than 18 years of age) in the conditions of "treatment of all conditions included in the category of malignant neoplasms [except lung cancer (small cell and non-small cell cancer), thyroid neoplasms, central

nervous system tumours, haematopoietic and lymphoid tissue neoplasms]", "treatment of malignant neoplasms of haematopoietic and lymphoid tissue" and "treatment of malignant neoplasms of the central nervous system" on the grounds that the product does not represent a significant therapeutic benefit because clinical studies would not be feasible.

2.1.38. Senaparib - EMEA-003034-PIP01-21

IMPACT Therapeutics US, Inc.; Treatment of metastatic castrate-resistant prostate cancer

Day 60 opinion

Oncology

Summary of Committee discussion:

Based on the assessment of this application the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for senaparib for all subsets of the paediatric population (0 to 18 years of age) in the condition treatment of malignant prostate neoplasms.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need.

2.1.39. Humanized monoclonal antibody of IgG1 sub-type targeting the human SEMA3A polypeptide - EMEA-002957-PIP02-21

Boehringer Ingelheim International GmbH; Treatment of diabetic retinopathy

Day 60 opinion

Ophthalmology

Summary of Committee discussion:

The PDCO granted a waiver for humanized monoclonal antibody of IgG1 sub-type targeting the human SEMA3A polypeptide for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of diabetic retinopathy.

2.1.40. Ofloxacin / dexamethasone (sodium phosphate) - EMEA-003031-PIP01-21

Laboratório Edol - Produtos Farmacêuticos S.A.; Prevention and treatment of ocular infections, inflammations and associated manifestations

Day 60 opinion

Ophthalmology

Summary of Committee discussion:

The PDCO re-discussed at Day 60 during the September 2021 plenary meeting an application for a product-specific waiver for dexamethasone (sodium phosphate) / ofloxacin. The PDCO confirmed all conclusions reached at Day 30 and adopted a positive opinion on a product specific waiver for dexamethasone (sodium phosphate) / ofloxacin for all subsets of the paediatric population (from birth to less than 18 years of age) in the condition of "prevention and treatment of ocular infections, inflammations and associated

manifestations" on the grounds of lack of significant therapeutic benefit.

2.1.41. Pyridine-3-carboxamide derivative (K-161) - EMEA-003048-PIP01-21

Kowa Pharmaceuticals Europe AG; Treatment of dry eye disease

Day 60 opinion

Ophthalmology

Summary of Committee discussion:

Based on the assessment of this application the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for the proposed product for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of dry eye disease.

2.1.42. Lutetium (^{177}Lu) chloride - EMEA-003038-PIP01-21

Eckert & Ziegler Radiopharma GmbH; Radiolabelling agent

Day 60 opinion

Other

Summary of Committee discussion:

Based on the assessment of this application, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for Lutetium (^{177}Lu) chloride for all subsets of the paediatric population (from birth to less than 18 years of age) in the condition 'radiolabelling agent' on the grounds of a lack of significant benefit.
The applicant is reminded to submit a PIP for every ^{177}Lu-linked carrier molecule intended for diagnostic or therapeutic use.

2.1.43. Depemokimab - EMEA-003051-PIP01-21

GlaxoSmithKline Trading Services Limited; Treatment of nasal polyposis

Day 60 opinion

Pneumology - Allergology

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for depemokimab for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of nasal polyposis on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need.

2.1.44. Yellow fever virus - EMEA-003030-PIP01-21

Prevention of Yellow fever disease

Day 60 opinion

Vaccines

Note: Withdrawal request received on 27 August 2021

2.2. Opinions on Compliance Check

The following compliance checks have been identified for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance.

2.2.1. Nivolumab / relatlimab - EMEA-C-002727-PIP01-19-M01

Bristol-Myers Squibb International Corporation; Treatment of melanoma

Day 30 opinion

Oncology

Summary of Committee discussion:

The PDCO adopted on 10 September 2021 an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision (P/0070/2021) of 17 March 2021.

2.2.2. Lonoctocog alfa - EMEA-C-001215-PIP01-11-M07

CSL Behring GmbH; Treatment of congenital factor VIII deficiency

Day 30 opinion

Haematology-Hemostaseology

Summary of Committee discussion:

The PDCO took note of outcomes of preceding partial compliance check procedures:

- EMEA-C1-001215-PIP01-11-M03
- EMEA-C1-001215-PIP01-11-M04

The PDCO adopted on 10 September 2021 an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision (P/0329/2019) of 10 September 2019.

2.2.3. Ganaxolone - EMEA-C1-002341-PIP01-18-M01

Marinus Pharmaceuticals Inc.; Treatment of cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder

Day 60 letter

Neurology

Summary of Committee discussion:

The PDCO discussed the completed study 3 1042-CDD-3001 and considered that this is compliant with the latest Agency's Decision (P/0171/2021) of 9 April 2021. However, few issues were raised and the PDCO recommended the applicant at the very least to perform a sensitivity analysis performed at the time of MAA in relation to the numbers of AEDs at baseline.

The PDCO finalised this partially completed compliance procedure on 10 September 2021.

2.2.4. Olipudase alfa - EMEA-C1-001600-PIP01-13-M02

Genzyme Europe B.V.; Treatment of Niemann-Pick disease

Day 30 letter

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of Committee discussion:

The PDCO discussed the completed study(ies) and considered that these are compliant with the latest Agency's Decision (P/0459/2020) of 18 August 2020.
The PDCO finalised this partially completed compliance procedure on 10 September 2021.

2.3. Opinions on Modification of an Agreed Paediatric Investigation Plan

2.3.1. Remimazolam - EMEA-001880-PIP02-19-M03

PAION Deutschland GmbH; Sedation / General anaesthesia

Day 60 opinion

Anaesthesiology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, which requested the removal of one of the 2 non-clinical studies in order to test the candidate formulations under development in adults rather than in animals, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency’s latest decision (P/0180/2021 of 10 May 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.2. Edoxaban tosylate - EMEA-000788-PIP02-11-M11

Daiichi Sankyo Europe GmbH; Treatment of venous thromboembolism / Prevention of venous thromboembolism / Prevention of arterial thromboembolism

Day 60 opinion

Cardiovascular Diseases / Haematology-Hemostaseology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, including additional information submitted between Day 30 and Day 60, the PDCO considered that the proposed changes could be accepted. The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0393/2020 of 23 October 2020).

The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.3. Dulaglutide - EMEA-000783-PIP01-09-M06

Eli Lilly and Company; Treatment of type 2 diabetes mellitus

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed change could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0175/2020 of 02 June 2020).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.4. Empagliflozin - EMEA-000828-PIP01-09-M09

Boehringer Ingelheim International GmbH; Treatment of type 2 diabetes mellitus

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0089/2021 of 19 March 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.5. Linagliptin - EMEA-000498-PIP01-08-M10

Boehringer Ingelheim International GmbH; Treatment of type 2 diabetes mellitus

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0088/2021 of 19 March 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.6. Recombinant human glutamic acid dexarboxylase (rhGAD65) - EMEA-000609-PIP01-09-M03

Diamyd Medical AB; Treatment of type 1 diabetes

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of Committee discussion:

Responses were received from the applicant and deemed satisfactory.
Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0318/2020 of 12 August 2020).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.7. Semaglutide - EMEA-001441-PIP03-17-M02

Novo Nordisk A/S; Treatment of obesity

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0326/2019 of 10 September 2019).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.8. Oxalobacter formigenes Strain HC-1 - Orphan - EMEA-000370-PIP02-18-M01

OxThera AB; Treatment of hyperoxaluria

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism / Uro-nephrology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0273/2019 of 14 August 2019).

The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.9. Recombinant human A disintegrin and metalloprotease with thrombospondin type-1 motifs 13 (rADAMTS13) - Orphan - EMEA-001160-PIP01-11-M02

Baxalta Innovations GmbH own by Takeda Pharmaceutical International AG; Treatment of thrombotic thrombocytopenic purpura

Day 60 opinion

Haematology-Hemostaseology

Summary of Committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that some proposed changes could be accepted. The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0324/2017 of 31 October 2017).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.10. Fostemsavir (tromethamine) - EMEA-001687-PIP01-14-M05

ViiV Healthcare UK Ltd; Treatment of human immunodeficiency virus (HIV-1) infection

Day 60 opinion

Infectious Diseases

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0268/2020 of 17 July 2020).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.11. Oteseconazole - EMEA-002392-PIP01-18-M02

Gedeon Richter Plc.; Treatment of vulvovaginal candidiasis

Day 60 opinion

Infectious Diseases

Summary of Committee discussion:

In the written response, the applicant addressed the remaining issues raised by the Committee. Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted. The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0147/2019 of 17 April 2019).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.12. Leriglitazone - Orphan - EMEA-002106-PIP01-16-M01

Minoryx Therapeutics S.L.; Treatment of adrenoleukodystrophy

Day 60 opinion

Neurology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted with the exception of maintaining the deferral, which has already expired anyway.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision.
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.13. Galcanezumab - EMEA-001860-PIP03-16-M06

Eli Lilly and Company Limited; Prevention of migraine headaches

Day 60 opinion

Neurology

Summary of Committee discussion:

The PDCO noted the replies of the applicant provided to the minutes of the PDCO.
The PDCO adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0136/2020 of 15/4/2020).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.14. Ganaxolone - Orphan - EMEA-002341-PIP01-18-M02

Marinus Pharmaceuticals Inc.; Treatment of cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder

Day 60 opinion

Neurology

Summary of Committee discussion:

Based on the responses submitted to the issues raised at D30, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0171/2021 of 9 April 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.15. Ozanimod hydrochloride - EMEA-001710-PIP02-14-M06

Celgene Europe B.V.; Treatment of multiple sclerosis

Day 60 opinion

Neurology

Summary of Committee discussion:

The applicant addressed the PDCO comments at Day 30.
The PDCO adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0233/2021 of 8 June 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.16. Abemaciclib - EMEA-002342-PIP01-18-M02

Eli Lilly and Company Limited; Treatment of Ewing's sarcoma

Day 60 opinion

Oncology

Summary of Committee discussion:

The PDCO re-discussed at day 60 during the September 2021 plenary meeting a modification for abemaciclib for the treatment of Ewing's sarcoma. The PDCO confirmed all the conclusions reached at Day 30. Based on the review of the documentation submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be acceptable. The main changes relate to timelines.
Therefore, the PDCO adopted a positive opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0376/2019 of 4 December 2019).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.17. Abemaciclib - EMEA-002342-PIP02-18-M01

Eli Lilly and Company Limited; Treatment of glioma / Treatment of neuroblastoma

Day 60 opinion

Oncology

Summary of Committee discussion:

The PDCO re-discussed at day 60, during the September 2021 plenary meeting, a modification for abemaciclib for the treatment of glioma and for the treatment of neuroblastoma.
Based on the review of the documentation submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that some of the proposed changes could be acceptable. The main changes relate to modification of timelines.
Therefore, the PDCO adopted a positive opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0021/2020 of 6 January 2020).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.18. Brigatinib - EMEA-002296-PIP01-17-M03

Takeda Pharm A/S; Treatment of anaplastic large cell lymphoma (ALCL) / Treatment of inflammatory myofibroblastic tumors (IMT) / Treatment of non-small cell lung cancer (NSCLC)

Day 60 opinion

Oncology

Summary of Committee discussion:

In the written response, applicant addressed the remaining issues raised by the Committee. Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0483/2020 of 9 December 2020).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.19. Imatinib (as imatinib mesylate) - EMEA-002643-PIP01-19-M01

Accord Healthcare S.L.U.; Treatment of Ph+ acute lymphoblastic leukaemia / Treatment of Ph+ chronic myeloid leukaemia

Day 60 opinion

Oncology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0171/2020 of 13 May 2020).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.20. Palbociclib - EMEA-002146-PIP01-17-M03

Pfizer Europe MA EEIG; Treatment of Ewing sarcoma

Day 60 opinion

Oncology

Summary of Committee discussion:

In the written response, the applicant addressed the remaining issues raised by the Committee.
Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted. The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision P/0091/2021 of 17 March 2021.
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.21. Temozolomide - EMEA-002634-PIP01-19-M01

Accord Healthcare S.L.U.; Treatment of malignant glioma

Day 60 opinion

Oncology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0147/2020 of 17 April 2020).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

The PDCO re-discussed this application, taking into account the additional information received from the applicant. The PDCO reminded the applicant to align the study dates of completion as part of any upcoming modification to ensure compliance at stage of validation for marketing authorisation application.

2.3.22. Fluocinolone acetonide - EMEA-000801-PIP03-16-M01

Alimera Sciences Limited; Treatment of chronic non-infectious uveitis / Secondary prevention of non-infectious uveitis

Day 60 opinion

Ophthalmology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0156/2017 of 8 June 2017).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.23. Ivacaftor / tezacaftor - Orphan - EMEA-001640-PIP01-14-M07

Vertex Pharmaceuticals (Ireland) Limited; Treatment of cystic fibrosis

Day 60 opinion

Other / Pneumology - Allergology

Summary of Committee discussion:

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0193/2020 of 15 May 2020). The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.24. Ivacaftor / tezacaftor / elexacaftor - Orphan - EMEA-002324-PIP01-17-M02

Vertex Pharmaceuticals (Ireland) Limited; Treatment of cystic fibrosis

Day 60 opinion

Other / Pneumology - Allergology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0397/2020 of 23 October 2020).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.25. Nintedanib - EMEA-001006-PIP05-18-M01

Boehringer Ingelheim International GmbH; Treatment of fibrosing interstitial lung diseases

Day 60 opinion

Pneumology - Allergology / Oncology

Summary of Committee discussion:

The applicant provided response after Day 30 which was deemed satisfactory by the PDCO. Based on the response the Committee considered that the proposed changes could be accepted.
The PDCO adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0150/2019 of 17 April 2019).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.26. Mirabegron - EMEA-000597-PIP03-15-M04

Astellas Pharma Europe B.V.; Treatment of neurogenic detrusor overactivity

Day 60 opinion

Uro-nephrology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, taking into account information submitted between Day 30 and Day 60, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0056/2017 of 16 March 2017).

2.3.27. Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP, live) - EMEA-001786-PIP01-15-M02

Merck Sharp & Dohme (Europe), Inc.; Prevention of Ebola disease

Day 60 opinion

Vaccines

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes to delay completion of study 1 and study 2 could be accepted.

The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0316/2020 of 14 August 2020)
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.28. CX-024414 (single-stranded, 5'-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2) - EMEA-002893-PIP01-20-M01

MODERNA BIOTECH SPAIN, S.L.; Prevention of COVID-19

Day 60 opinion

Vaccines / Infectious Diseases

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that most of the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0481/2020 of 30 November 2020).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.29. Acalabrutinib - Orphan - EMEA-001796-PIP03-16-M02

Acerta Pharma, BV; Treatment of mature B cell neoplasms

Day 30 opinion

Oncology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed change could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0062/2019 of 15 March 2019).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.30. Selpercatinib - EMEA-002544-PIP01-18-M01

Eli Lilly and Company; Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue neoplasms)

Day 30 opinion

Oncology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as

set in the Agency's latest decision (P/0369/2019 of 8 November 2019).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.31. Tozinameran (BNT162b2) - EMEA-002861-PIP02-20-M02

BioNTech Manufacturing GmbH; Prevention of coronavirus disease 2019 (COVID-19)

Day 3 opinion

Vaccines / Infectious Diseases

Note: Adopted via written procedure on 20 August 2021

2.4. Opinions on Re-examinations

No item

2.5. Opinions on Review of Granted Waivers

No item

2.6. Finalisation and adoption of Opinions

No item

2.7. Partial Compliance Checks completed by EMA

The following partial compliance checks have been identified by the PME coordinator and PDCO rapporteur as not needing to be referred to the PDCO for discussion. The PDCO has been informed in writing.

2.7.1. *Neisseria meningitidis* serogroup W polysaccharide conjugated to tetanus toxoid / *N. meningitidis* serogroup Y polysaccharide conjugated to tetanus toxoid / *N. meningitidis* serogroup A polysaccharide conjugated to tetanus toxoid / *N. meningitidis* serogroup C polysaccharide conjugated to tetanus toxoid - EMEA-C2-001930-PIP01-16-M03

Sanofi Pasteur; Prevention of invasive meningococcal disease

Day 30 letter

Vaccines

2.7.2. Durvalumab - EMEA-C2-002028-PIP01-16-M02

AstraZeneca AB; Treatment of malignant neoplasms of lymphoid tissue

Day 30 letter

Oncology

2.7.3. Tremelimumab - EMEA-C2-002029-PIP01-16-M02

AstraZeneca AB; Treatment of malignant neoplasms of lymphoid tissue

Day 30 letter

Oncology

2.7.4. Ravulizumab - EMEA-C2-001943-PIP01-16-M06

Alexion Europe SAS; Treatment of atypical haemolytic uremic syndrome

Day 30 letter

Uro-nephrology

2.7.5. Ravulizumab - EMEA-C3-002077-PIP01-16-M04

Alexion Europe SAS; Treatment of paroxysmal nocturnal haemoglobinuria

Day 30 letter

Haematology-Hemostaseology

2.7.6. Mirabegron - EMEA-C4-000597-PIP03-15-M03

Astellas Pharma Europe B.V.; Treatment of neurogenic detrusor overactivity

Day 30 letter

Uro-nephrology

2.7.7. Bupivacaine - EMEA-C1-000877-PIP03-17-M03

Pacira Ltd; Postsurgical analgesia

Day 30 letter

Pain

Note: Adopted via written procedure on 9 August 2021

3. Discussion of applications

Some information related to this section cannot be disclosed at the present time as it is deemed to contain commercially confidential information.

3.1. Discussions on Products D90-D60-D30

3.1.1. Peptide derivative of glucagon-like-peptide 1 and glucagon with fatty acid side chain - EMEA-002942-PIP01-20

Treatment of non-alcoholic steatohepatitis

Day 90 discussion

Gastroenterology-Hepatology

3.1.2. Marzeptacog alfa (activated) - Orphan - EMEA-002270-PIP03-20

Catalyst Biosciences, Inc.; Treatment of haemophilia A

Day 90 discussion

Haematology-Hemostaseology

3.1.3. Marzeptacog alfa (activated) - Orphan - EMEA-002270-PIP04-20

Catalyst Biosciences, Inc.; Treatment of haemophilia B

Day 90 discussion

Haematology-Hemostaseology

3.1.4. Ravulizumab - EMEA-001943-PIP04-20

Aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder

Day 90 discussion

Neurology

3.1.5. Satralizumab - Orphan - EMEA-001625-PIP02-21

Roche Registration GmbH; Treatment of myasthenia gravis

Day 90 discussion

Neurology

3.1.6. Lutetium (^{177}Lu) oxodotreotide - Orphan - EMEA-002950-PIP01-20

Advanced Accelerator Applications; Gastroenteropancreatic neuroendocrine tumours (GEP-NETs)

Day 90 discussion

Oncology

3.1.7. Magrolimab - Orphan - EMEA-002819-PIP01-20

Gilead Sciences International Ltd; Treatment of myelodysplastic syndromes (including juvenile myelomonocytic leukaemia) / Treatment of acute myeloid leukaemia

Day 90 discussion

Oncology

3.1.8. 2'-O-(2-methoxyethyl) phosphorothioate antisense oligonucleotide targeting CD49d RNA - Orphan - EMEA-002981-PIP01-21

Antisense Therapeutics Limited; Treatment of Duchenne muscular dystrophy

Day 90 discussion

Other

3.1.9. Evenamide - EMEA-002519-PIP03-21

Treatment of schizophrenia

Day 90 discussion

Psychiatry

3.1.10. *Neisseria meningitidis* serogroup B protein-based active substance / Recombinant *Neisseria meningitidis* serogroup B protein 1 / Recombinant *Neisseria meningitidis* serogroup B protein 3 / Recombinant *Neisseria meningitidis* serogroup B protein 2 - EMEA-002954-PIP02-21

Prevention of meningococcal disease

Day 90 discussion

Vaccines

3.1.11. Dupilumab - EMEA-001501-PIP09-21

Treatment of chronic inducible cold urticaria

Day 60 discussion

Dermatology

3.1.12. Phospholipid esters from herring roe - EMEA-003053-PIP01-21

Treatment of psoriasis

Day 60 discussion

Dermatology

3.1.13. Bilastine - EMEA-000347-PIP06-21

Treatment of acute type I hypersensitivity reactions either alone, or in severe cases as an adjunctive agent

Day 60 discussion

Dermatology / Pneumology - Allergology / Oto-rhino-laryngology

Note: Withdrawal request received on 8 September 2021

3.1.14. Ibutamoren mesilate - Orphan - EMEA-003032-PIP01-21

Lumos Pharma, Inc.; Treatment of growth hormone deficiency

Day 60 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.15. Zinc gluconate / alisitol / retinyl palmitate - Orphan - EMEA-002198-PIP01-21

Vanessa Research Magyarorszag Kft/Vanessa Research Hungary Ltd; Treatment of microvillus inclusion disease

Day 60 discussion

Gastroenterology-Hepatology

3.1.16. Mitapivat - Orphan - EMEA-002684-PIP02-21

Agios Netherlands B.V.; Treatment of thalassaemia

Day 60 discussion

Haematology-Hemostaseology

3.1.17. Rozanolixizumab - Orphan - EMEA-002681-PIP02-21

UCB Pharma S.A; Treatment of immune thrombocytopenia

Day 60 discussion

Haematology-Hemostaseology

3.1.18. Autologous bone marrow derived CD34+cells transduced with the lentiviral vector CL20-4i-EF1α-hγc-OPT - Orphan - EMEA-003050-PIP01-21

Mustang Bio, Inc.; Treatment of X-linked severe combined immunodeficiency (XSCID)

Day 60 discussion

Immunology-Rheumatology-Transplantation

3.1.19. ECT-001-CB (Haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R,4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate) - Orphan - EMEA-003025-PIP02-21

ExCellThera; Allogeneic haematopoietic stem cell transplantation

Day 60 discussion

Immunology-Rheumatology-Transplantation / Oncology / Haematology-Hemostaseology

3.1.20. Reparixin - Orphan - EMEA-001693-PIP03-21

Dompé farmaceutici S.p.A.; Treatment of coronavirus disease 2019 (COVID-19)

Day 60 discussion

Infectious Diseases

3.1.21. Alprazolam - EMEA-003043-PIP01-21

Treatment of epileptic seizures

Day 60 discussion

Neurology

3.1.22. Invimestrocel - EMEA-002317-PIP02-21

Treatment of acute ischaemic stroke / Acute ischaemic stroke

Day 60 discussion

Neurology

3.1.23. Rozanolixizumab - EMEA-002681-PIP03-21

Treatment of myelin oligodendrocyte glycoprotein antibody-associated disease

Day 60 discussion

Neurology

3.1.24. 1-[({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6- methoxyquinolin-7-yl}oxy)methyl]cyclopropan-1-amine bishydrocloride - Orphan - EMEA-002486-PIP04-21

Advenchen Laboratories, LLC.; Treatment of soft tissue sarcomas

Day 60 discussion

Oncology

3.1.25. Plinabulin - EMEA-003054-PIP01-21

Chemotherapy-induced neutropenia

Day 60 discussion

Oncology

3.1.26. Tazemetostat - Orphan - EMEA-003055-PIP01-21

Epizyme, Inc.; Mature B cell neoplasms / Soft tissue sarcomas / Treatment of soft tissue sarcomas / Treatment of mature B cell neoplasms

Day 60 discussion

Oncology

3.1.27. Pabinafusp alfa - Orphan - EMEA-003033-PIP01-21

JCR Pharmaceuticals Co., Ltd.; Mucopolysaccharidosis type II

Day 60 discussion

Other

3.1.28. EMEA-003052-PIP01-21

Treatment of cystic fibrosis

Day 60 discussion

Pneumology - Allergology

3.1.29. L-Carnitine / glucose / calcium chloride dihydrate / magnesium chloride hexahydrate / sodium lactate / sodium chloride - EMEA-003049-PIP01-21

Treatment of patients in need of peritoneal dialysis

Day 60 discussion

Uro-nephrology

3.1.30. *Neisseria meningitidis* serogroup B fHbp subfamily B / *Neisseria meningitidis* serogroup B fHbp subfamily A / *Neisseria meningitidis* group Y polysaccharide conjugated to tetanus toxoid carrier protein / *Neisseria meningitidis* group W-135 polysaccharide conjugated to tetanus toxoid carrier protein / *Neisseria meningitidis* group C polysaccharide conjugated to tetanus toxoid carrier protein / *Neisseria meningitidis* group A polysaccharide conjugated to tetanus toxoid carrier protein - EMEA-002814-PIP02-21

Invasive disease caused by *Neisseria meningitidis* group A, B, C, W and Y from 2 months of age

Day 60 discussion

Vaccines

3.1.31. SARS-CoV-2, produced in Vero cells (inactivated) - EMEA-003057-PIP01-21

Prevention of coronavirus disease 2019 (COVID-19)

Day 60 discussion

Vaccines

3.1.32. Amlodipine / ramipril - EMEA-003070-PIP01-21

Treatment of hypertension

Day 30 discussion

Cardiovascular Diseases

3.1.33. Furosemide / eplerenone - EMEA-003065-PIP01-21

Treatment of heart failure

Day 30 discussion

Cardiovascular Diseases

3.1.34. Humanised KLB / FGFR1c monoclonal antibody - EMEA-003058-PIP01-21

Treatment of non-alcoholic steatohepatitis

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.35. Semaglutide / cagrilintide - EMEA-003059-PIP01-21

Treatment of obesity

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.36. Tezepelumab - EMEA-001613-PIP03-21

Eosinophilic esophagitis

Day 30 discussion

Gastroenterology-Hepatology

3.1.37. Clazakizumab - EMEA-001371-PIP02-21

Treatment of chronic active antibody mediated rejection (AMR) in kidney transplantation

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.1.38. Human normal immunoglobulin - EMEA-003076-PIP01-21

Treatment of antibody deficiency

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.1.39. Retinol palmitate - Orphan - EMEA-003073-PIP01-21

PROVEPHARM SAS; Prevention of bronchopulmonary dysplasia

Day 30 discussion

Neonatology - Paediatric Intensive Care

3.1.40. Cannabidiol - EMEA-001964-PIP03-21

Treatment of epilepsy with myoclonic atonic seizures

Day 30 discussion

Neurology

3.1.41. Censavudine - EMEA-003075-PIP01-21

Aicardi-Goutières syndrome

Day 30 discussion

Neurology

3.1.42. Verdiperstat - Orphan - EMEA-002708-PIP02-21

Biohaven Pharmaceutical Ireland DAC; Treatment of amyotrophic lateral sclerosis

Day 30 discussion

Neurology

3.1.43. Adagrasib - EMEA-003068-PIP01-21

Treatment of non-small cell lung cancer

Day 30 discussion

Oncology

3.1.44. Adagrasib - EMEA-003068-PIP02-21

Treatment of colorectal cancer

Day 30 discussion

Oncology

3.1.45. Adavosertib - EMEA-003069-PIP01-21

Treatment of malignant endometrial neoplasms / Treatment of malignant pancreatic neoplasms

Day 30 discussion

Oncology

3.1.46. Autologous tumour-infiltrating lymphocytes (TILs) isolated from a patient's cancer tissue and expanded ex vivo - EMEA-003072-PIP01-21

Treatment of advanced melanoma

Day 30 discussion

Oncology

3.1.47. Ofranergene obadenovec - Orphan - EMEA-003062-PIP01-21

Vascular Biogenics Ltd. (VBL Therapeutics); Treatment of ovarian cancer / Treatment of primary peritoneal cancer / Treatment of fallopian tube cancer

Day 30 discussion

Oncology

3.1.48. Pamrevlumab - EMEA-002979-PIP03-21

Treatment of pancreatic cancer

Day 30 discussion

Oncology

3.1.49. Vibostolimab / pembrolizumab - EMEA-003063-PIP01-21

Treatment of malignant neoplasms of the central nervous system / Treatment of all conditions included in the category of malignant neoplasms (except nervous system, haematopoietic and lymphoid tissue)

Day 30 discussion

Oncology

3.1.50. Cedazuridine / decitabine - EMEA-003071-PIP01-21

Acute myeloid leukaemia

Day 30 discussion

Oncology / Haematology-Hemostaseology

3.1.51. Otenaproxesul - EMEA-003061-PIP01-21

Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylarthritis and juvenile idiopathic arthritis)

Day 30 discussion

Pain

3.1.52. Benralizumab - EMEA-001214-PIP08-21

Treatment of non-cystic fibrosis bronchiectasis with an eosinophilic phenotype

Day 30 discussion

Pneumology - Allergology

3.1.53. Bis-(3-deoxy-3-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-beta-D-galactopyranosyl) sulfane - Orphan - EMEA-003060-PIP01-21

Galecto Biotech AB; Idiopathic pulmonary fibrosis

Day 30 discussion

Pneumology - Allergology

3.1.54. Depemokimab - EMEA-003051-PIP02-21

Eosinophilic granulomatosis with polyangiitis (EGPA)

Day 30 discussion

Pneumology - Allergology

3.1.55. Depemokimab - EMEA-003051-PIP03-21

Treatment of hypereosinophilic syndrome (HES)

Day 30 discussion

Pneumology - Allergology

3.1.56. Human alpha1-proteinase inhibitor (also called Alpha-1 Antitrypsin) - EMEA-001525-PIP02-21

Treatment of emphysema secondary to congenital deficiency of alpha-1 antitrypsin

Day 30 discussion

Pneumology - Allergology

3.1.57. Pamrevlumab - EMEA-002979-PIP02-21

Idiopathic pulmonary fibrosis

Day 30 discussion

Pneumology - Allergology

3.1.58. Ilofotase alfa - EMEA-003067-PIP01-21

Treatment of sepsis-associated acute kidney injury

Day 30 discussion

Uro-nephrology

3.1.59. Lademirsen - Orphan - EMEA-003064-PIP01-21

Genzyme Europe B.V.; Treatment of Alport syndrome

Day 30 discussion

Uro-nephrology

3.1.60. Influenza virus surface antigen (haemagglutinin and neuraminidase) of strain A/H5N1 - EMEA-002869-PIP02-21

Influenza due to identified zoonotic or pandemic influenza virus

Day 30 discussion

Vaccines

3.1.61. Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A/H5N1 - EMEA-002869-PIP01-21

Influenza due to identified zoonotic or pandemic influenza virus

Day 30 discussion

Vaccines

3.1.62. Inactivated poliovirus: type 3 (Saukett strain) / Inactivated poliovirus: type 2 (MEF-1 strain) / Inactivated poliovirus: type 1 (Mahoney strain) / *Bordetella pertussis* antigen: Pertactin / *Bordetella pertussis* antigen: Filamentous Haemagglutinin / *Bordetella pertussis* antigen: Pertussis toxoid / Tetanus toxoid / Diphtheria toxoid - EMEA-003066-PIP01-21

Prevention of infectious diseases caused by *Corynebacterium diphtheriae*, *Clostridium tetani*, *Bordetella pertussis*, Poliovirus types 1, 2 and 3

Day 30 discussion

Vaccines / Infectious Diseases

3.1.63. RSV F protein - EMEA-003094-PIP01-21

Prevention of lower respiratory tract disease caused by respiratory syncytial virus

Day 30 discussion

Vaccines / Infectious Diseases

3.1.64. Whole-cell heat-inactivated bacterial strains of *Escherichia coli / Klebsiella pneumoniae / Proteus vulgaris / Enterococcus faecalis* - EMEA-003026-PIP02-21

Prevention of recurrent urinary tract infections (R-UTIs)

Day 30 discussion

Vaccines / Infectious Diseases / Uro-nephrology

3.2. Discussions on Compliance Check

The following compliance checks have been identified for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance.

3.2.1. Ceftobiprole medocaril (sodium) - EMEA-C1-000205-PIP02-11-M04

Basilea Pharmaceutica International Ltd; Treatment of pneumonia

Day 30 discussion

Infectious Diseases

3.2.2. Oseltamivir (phosphate) - EMEA-C-000365-PIP01-08-M12

Roche Registration GmbH; Treatment and prevention of influenza

Day 30 discussion

Infectious Diseases

3.2.3. Zanubrutinib - EMEA-C1-002354-PIP02-18

BeiGene Ireland Ltd; Treatment of mature B cell neoplasms (excluding lymphoplasmacytic lymphoma)

Day 30 discussion

Oncology

3.2.4. Ponatinib - EMEA-C2-001186-PIP01-11-M02

Incyte Biosciences Distribution B.V.; Treatment of chronic myeloid leukaemia

Day 30 discussion

Oncology

Note: Withdrawal request received on 3 September 2021

3.3. Discussions on Modification of an Agreed Paediatric Investigation Plan

3.3.1. Bilastine - EMEA-000347-PIP02-16-M03

Faes Farma S.A.; Treatment of allergic conjunctivitis

Day 30 discussion

Ophthalmology

3.3.2. 3,4-Dimethoxy-N-methylbenzohydroxamic acid / deferoxamine mesylate / alfa-ketoglutaric acid / arginine / alanine / glycine / aspartic acid / tryptophan / N-acetyl-histidine (monohydrate) / histidine / calcium chloride (dihydrate) / magnesium chloride (hexahydrate) / potassium chloride / sodium chloride - EMEA-002735-PIP03-20-M01

Dr. Franz Köhler Chemie GmbH; Heart transplantation

Day 30 discussion

Cardiovascular Diseases

3.3.3. Azilsartan medoxomil - EMEA-000237-PIP01-08-M10

Takeda Development Centre Europe Ltd; Treatment of hypertension

Day 30 discussion

Cardiovascular Diseases

3.3.4. Macitentan - Orphan - EMEA-001032-PIP01-10-M04

Janssen-Cilag International NV; Treatment of pulmonary arterial hypertension / Treatment of systemic sclerosis / Treatment of idiopathic pulmonary fibrosis

Day 30 discussion

Cardiovascular Diseases

3.3.5. Vericiguat - EMEA-001636-PIP01-14-M02

Bayer AG; Treatment of left ventricular failure

Day 30 discussion

Cardiovascular Diseases

3.3.6. Glycopyrronium bromide - EMEA-002383-PIP01-18-M01

Dr. August Wolff GmbH & Co. KG - Arzneimittel; Treatment of hyperhidrosis

Day 30 discussion

Dermatology

3.3.7. Cotadutide - EMEA-002287-PIP01-17-M03

AstraZeneca AB; Treatment of type 2 diabetes mellitus

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.3.8. Evinacumab - EMEA-002298-PIP01-17-M03

Regeneron Ireland DAC; Treatment of elevated cholesterol

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.3.9. Sodium zirconium cyclosilicate - EMEA-001539-PIP01-13-M05

AstraZeneca AB; Treatment of hyperkalaemia

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.3.10. Naloxegol (as naloxegol oxalate) - EMEA-001146-PIP01-11-M07

Kyowa Kirin Pharmaceutical Development Limited; Treatment of opioid-induced constipation

Day 30 discussion

Gastroenterology-Hepatology

3.3.11. Marstacimab - Orphan - EMEA-002285-PIP02-19-M01

Pfizer Europe MAA EEIG; Treatment of congenital haemophilia A / Treatment of congenital haemophilia B

Day 30 discussion

Haematology-Hemostaseology

3.3.12. Vonicog alfa - EMEA-001164-PIP01-11-M05

Baxalta Innovations GmbH; Treatment of Von Willebrand disease

Day 30 discussion

Haematology-Hemostaseology

3.3.13. Upadacitinib - EMEA-001741-PIP01-14-M05

AbbVie Ltd; Treatment of chronic idiopathic arthritis

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.3.14. Baloxavir marboxil - EMEA-002440-PIP01-18-M02

Roche Registration GmbH; Prevention of influenza / Treatment of influenza

Day 30 discussion

Infectious Diseases

3.3.15. Ceftobiprole medocaril sodium - EMEA-000205-PIP02-11-M05

Basilea Pharmaceutica International Ltd.; Treatment of pneumonia

Day 30 discussion

Infectious Diseases

3.3.16. Dalbavancin - EMEA-000016-PIP01-07-M08

Allergan Pharmaceuticals International Limited; Treatment of acute bacterial skin and skin structure infections (ABSSSI)

Day 30 discussion

Infectious Diseases

3.3.17. Isavuconazonium (sulfate) - Orphan - EMEA-001301-PIP02-12-M04

Basilea Pharmaceutica International Ltd.; Treatment of invasive aspergillosis / Treatment of mucormycosis

Day 30 discussion

Infectious Diseases

3.3.18. Oritavancin (diphosphate) - EMEA-001270-PIP01-12-M04

Menarini International Operations Luxembourg S.A.; Treatment of acute bacterial skin and

skin structure infections

Day 30 discussion

Infectious Diseases

3.3.19. Pretomanid - Orphan - EMEA-002115-PIP01-17-M04

Global Alliance for TB Drug Development; Treatment of multi-drug-resistant tuberculosis

Day 30 discussion

Infectious Diseases

3.3.20. Rilpivirine (RPV) / dolutegravir (DTG) - EMEA-001750-PIP01-15-M05

ViiV Healthcare UK Limited; B24 Unspecified human immunodeficiency virus (HIV) disease

Day 30 discussion

Infectious Diseases

3.3.21. Sotrovimab - EMEA-002899-PIP01-20-M01

GlaxoSmithKline Trading Services Ltd; Treatment of coronavirus disease 2019 (COVID-19)

Day 30 discussion

Infectious Diseases

3.3.22. Tecovirimat monohydrate - Orphan - EMEA-001205-PIP02-19-M01

SIGA Technologies, Inc.; Orthopoxvirus disease (smallpox, monkeypox, cowpox, and vaccinia complications)

Day 30 discussion

Infectious Diseases

3.3.23. Tenofovir alafenamide / emtricitabine / bictegravir - EMEA-001766-PIP01-15-M04

Gilead Sciences International Ltd.; Treatment of human immunodeficiency virus (HIV) infection

Day 30 discussion

Infectious Diseases

3.3.24. Erenumab - EMEA-001664-PIP02-15-M05

Novartis Europharm Limited; Prevention of migraine headaches

Day 30 discussion

Neurology

3.3.25. Perampanel - EMEA-000467-PIP01-08-M15

Eisai Europe Limited; Treatment of treatment-resistant epilepsies

Day 30 discussion

Neurology

3.3.26. Soticlestat - EMEA-002572-PIP02-19-M01

Takeda Pharma A/S; Dravet syndrome / Lennox-Gastaut syndrome

Day 30 discussion

Neurology

3.3.27. Cabozantinib - Orphan - EMEA-001143-PIP01-11-M04

Ipsen Pharma; Treatment of malignant solid tumours

Day 30 discussion

Oncology

3.3.28. Cyclophosphamide - EMEA-002644-PIP01-19-M01

Accord Healthcare S.L.U.; Treatment of all malignant neoplasms

Day 30 discussion

Oncology

3.3.29. Larotrectinib - EMEA-001971-PIP02-16-M04

Bayer AG; Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms)

Day 30 discussion

Oncology

3.3.30. Regorafenib - EMEA-001178-PIP01-11-M06

Bayer AG; Treatment of all conditions contained in the category of malignant neoplasms (except haematopoietic and lymphoid tissue)

Day 30 discussion

Oncology

3.3.31. Ruxolitinib phosphate - EMEA-000901-PIP04-17-M02

Novartis Europharm Limited; Chronic graft versus host disease

Day 30 discussion

Oncology

3.3.32. Inotuzumab ozogamicin - Orphan - EMEA-001429-PIP01-13-M04

Pfizer Europe MA EEIG; Treatment of acute lymphoblastic leukaemia

Day 30 discussion

Oncology / Haematology-Hemostaseology

3.3.33. Vamorolone - Orphan - EMEA-001794-PIP02-16-M04

ReveraGen BioPharma Ltd; Treatment of Duchenne muscular dystrophy

Day 30 discussion

Other

3.3.34. Methoxflurane - EMEA-000334-PIP01-08-M10

Medical Developments UK Ltd; Treatment of acute pain

Day 30 discussion

Pain

3.3.35. Molgramostim - Orphan - EMEA-002282-PIP01-17-M01

Savara Aps; Treatment of pulmonary alveolar proteinosis

Day 30 discussion

Pneumology - Allergology

3.3.36. Tezepelumab - EMEA-001613-PIP01-14-M05

AstraZeneca AB; Treatment of asthma

Day 30 discussion

Pneumology - Allergology

3.3.37. Lumasiran sodium - Orphan - EMEA-002079-PIP01-16-M02

Alnylam UK Limited; Treatment of primary hyperoxaluria type 1

Day 30 discussion

Uro-nephrology

3.3.38. Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain B (Victoria lineage) / Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain B (Yamagata lineage) / Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H3N2) / Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H1N1) - EMEA-002068-PIP01-16-M04

Seqirus Netherlands; Influenza

Day 30 discussion

Vaccines

3.3.39. NVX-CoV2373 - EMEA-002941-PIP01-20-M01

Novavax CZ, a.s.; Prevention of coronavirus disease 2019 (COVID-19)

Day 30 discussion

Vaccines

4. Nominations

Information related to this section cannot be disclosed at the present time as it is deemed to contain commercially confidential information.

4.1. List of letters of intent received for submission of applications with start of procedure 14 September 2021 for Nomination of Rapporteur and Peer reviewer

Summary of Committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.2. Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver

Summary of Committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.3. Nominations for other activities

Summary of Committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

5. Scientific Advice Working Party (SAWP) and Paediatric Committee (PDCO) Interaction

Information related to this section cannot be disclosed at the present time as it is deemed

to contain commercially confidential information.

5.1. New Scientific Advice

5.2. Final Scientific Advice (Reports and Scientific Advice letters)

No item

6. Discussion on the applicability of class waivers

6.1. Discussions on the applicability of class waiver for products

No item

7. Discussion on the inclusion of an indication within a condition in an agreed PIP/waiver

7.1. Discussion on the possibility to include an indication within a condition in an agreed PIP/waiver

7.1.1. Stivarga - EMEA-001178-PIP01-11-M05

Bayer; Treatment of all conditions contained in the category of malignant neoplasms (except haematopoietic and lymphoid tissue)

Proposed indication: Treatment in adults in glioblastoma multiforme (GBM), sarcoma (such as bone sarcoma or non-adipocytic soft tissue sarcoma)

Oncology

Summary of Committee discussion:

The letter was noted.

8. Annual reports on deferrals

The members of the PDCO took note of the products listed in the Annex B.

9. Organisational, regulatory and methodological matters

9.1. Mandate and organisation of the PDCO

9.1.1. Update on PDCO member(s)/alternate(s) mandate status

No item

9.1.2. Pilot – Relaunch of face to face Scientific Committee Meetings

Summary of Committee discussion:

The PDCO was informed about the expected set-up for returning to Committee face-to-face meetings. Members and alternates will receive a survey on their likely attendance in person to the December PDCO meeting. The outcome will be discussed with the PDCO chair for agreement whether the December meeting goes ahead as face-to-face or fully remote meeting. The chair welcomed EMA's offer to return to face-to-face meetings.

9.1.3. PDCO Rules of Procedure – revision

Summary of Committee discussion:

To reflect the meeting approach for the pilot for the relaunch of face to face committee meetings, the PDCO Rules of Procedure required revision. The opportunity was taken to introduce some other changes to facilitate the functioning of the committees and for consistency reasons.

The Committee adopted the revised Rules of Procedure via written procedure on 22 September 2021.

9.2. Coordination with EMA Scientific Committees or CMDh-v

9.2.1. Committee for Medicinal Products for Human Use (CHMP)

Summary of Committee discussion:

No item

9.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

9.3.1. Non-clinical Working Group: D30 Products identified

PDCO member: Karen van Malderen

Summary of Committee discussion:

The chair of the Non-clinical Working Group (NcWG) identified the products which will

require NcWG evaluation and discussion.

9.3.2. Formulation Working Group

PDCO member: Brian Aylward

Summary of Committee discussion:

The Chair of the Formulation Working Group (FWG) identified the products which will require FWG evaluation and discussion.

9.3.3. Patients and Consumers Working Party (PCWP) / Healthcare Professionals Working Party (HCPWP) on 21-22 September 2021

Summary of Committee discussion:

The agenda for the Patients and Consumers Working Party (PCWP) / Healthcare Professionals Working Party (HCPWP) on 21-22 September 2021 was presented for information.

9.4. Cooperation within the EU regulatory network

9.4.1. European Network of Paediatric Research (Enpr) - European Medicines Agency (EMA)

Summary of Committee discussion:

No item

9.5. Cooperation with International Regulators

No item

9.6. Contacts of the PDCO with external parties and interaction with the Interested Parties to the Committee

No item

9.7. PDCO work plan

No item

9.8. Planning and reporting

No item

10. Any other business

10.1. COVID -19 update

Summary of Committee discussion:

Postponed to next month.

10.2. Project Lifecycle Regulations Submissions Raw Data (LRSR)

Summary of Committee discussion:

EMA's Lifecycle Regulatory Submissions Raw Data project is focusing on utilising raw data to generate evidence for better and more efficient regulatory decision making.

This project is part of the Data Analytics Programme also known as the Agency's vehicle for evolving to data-driven medicines regulation and constitutes one of the priority recommendations of the EMA-HMA Big Data Taskforce.

The project's background, work done so far, and next steps were presented.

PDCO members highlighted the importance of this project and suggested the project team to explore interaction with open data initiatives.

10.3. Project on paediatric first-line tuberculosis medicines

Summary of Committee discussion:

EMA International Affairs Division (AF-IA) is engaging with WHO (Euro and HQ) to stimulate the submission and approval of first-line prioritised TB medicines for children (and adults) as there are high unmet needs in the EU/EEA, with either lack of approval (paediatric medicines) or outdated dosing. The medicines chosen are those recommended in the current WHO guidelines. The current estimates (WHO 2019 data) show about 50000 reported cases including ~3000 paediatric cases (noting significant under-reporting from countries with high incidence). Indian companies have prequalified medicines for children, including appropriately doses dispersible tablets of fixed drug combinations and adult ones. Despite various attempts by Member states these medicines have not been submitted. The reasons are mostly based on costs and need for human resources.

EMA has indicated that it will provide all help possible (regulatory and pre-submission, including review of the quality files). Fee reductions/waivers will be provided and arrangements for translations can be discussed. In addition AF-IA is also contacting trade associations.

PDCO is asked for support and informed as depending on the legal basis, some applications may require a PIP. PDCO expressed its full support and asked to be kept updated.

11. Breakout sessions

11.1. Internal PDCO Operations

Summary of Committee discussion:

The PDCO discussed issues relating to the PDCO-SAWP interaction.

11.2. Neonatology

Summary of Committee discussion:

The Neonatology and Vaccines Breakout session were joint and the Committee discussed COVID vaccination in pregnancy.

11.3. Vaccines

Summary of Committee discussion:

The Neonatology and Vaccines Breakout session were joint and the Committee discussed COVID vaccination in pregnancy.

11.4. Paediatric oncology

Summary of Committee discussion:

The Committee discussed aspects related to applications of PIPs for oncology products.

11.5. PDCO-SAWP interaction and process improvement

Summary of Committee discussion:

The PDCO discussed the interaction between the SAWP and the PDCO and ways to improve it.

The Chair thanked all participants and closed the meeting.

12. List of participants

List of participants including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 7-10 September 2021 meeting.

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Koenraad Norga	Chair	Belgium	When chairing the meeting: To be replaced for discussions, final deliberations and voting on: When not chairing the meeting: No participation in final deliberations and voting on:	2.1.17. Respiratory Syncytial Virus (RSV) PreF3 recombinant Fusion protein - EMEA-002904-PIP01-20 2.1.43. Depemokimab - EMEA-003051-PIP01-21 3.1.52. Depemokimab - EMEA-003051-PIP02-21 3.1.53. Depemokimab - EMEA-003051-PIP03-21 3.3.21. Sotrovimab - EMEA-002899-PIP01-20-M01
Karl-Heinz Huemer	Member	Austria	No interests declared	
Johanna Wernsperger	Alternate	Austria	No interests declared	
Karen Van Malderen	Alternate	Belgium	No interests declared	
Dimitar Roussinov	Member	Bulgaria	No restrictions applicable for the meeting	
Tereza Bazantova	Alternate	Czechia	No interests declared	
Nanna Borup Johansen	Member	Denmark	No interests declared	
Irja Lutsar	Member	Estonia	No interests declared	
Jana Lass	Alternate	Estonia	No interests declared	
Pauliina Lehtolainen-Dalkilic	Member	Finland	No interests declared	
Anne Paavola	Alternate	Finland	No interests declared	
Sylvie Benchetrit	Member	France	No interests declared	
Dominique Ploin	Alternate	France	No interests declared	
Sabine Scherer	Member (Vice-Chair)	Germany	No interests declared	
Yuansheng Sun	Alternate	Germany	No interests declared	
Eleni Katsomiti	Member	Greece	No interests declared	
Anastasia Mountaki	Alternate	Greece	No interests declared	
Ágnes Gyurasics	Member (CHMP member)	Hungary	No interests declared	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Brian Aylward	Member	Ireland	No interests declared	
Sara Galluzzo	Member	Italy	No interests declared	
Dina Apele-Freimane	Member	Latvia	No restrictions applicable for the meeting	
Dovile Zacharkiene	Member	Lithuania	No interests declared	
Silvijus Abramavicius	Alternate	Lithuania	No restrictions applicable for the meeting	
Carola de Beaufort	Member (CHMP alternate)	Luxembourg	No interests declared	
Herbert Lenicker	Alternate	Malta	No interests declared	
Roderick Houwen	Member	Netherlands	No restrictions applicable for the meeting	
Maaike van Dartel	Alternate	Netherlands	No interests declared	
Siri Wang	Member	Norway	No interests declared	
Anette Solli Karlsen	Alternate	Norway	No interests declared	
Marek Migdal	Member	Poland	No restrictions applicable for the meeting	
Helena Fonseca	Member	Portugal	No interests declared	
Hugo Tavares	Alternate	Portugal	No interests declared	
Dana Gabriela Marin	Member (CHMP alternate)	Romania	No interests declared	
Peter Sisovsky	Member	Slovakia	No interests declared	
Peter Szitanyi	Alternate	Slovakia	No interests declared	
Stefan Grosek	Member	Slovenia	No interests declared	
Fernando de Andrés Trelles	Member	Spain	No interests declared	
Maria Jesus Fernández Cortizo	Alternate	Spain	No interests declared	
Eva Agurell	Member	Sweden	No interests declared	
Johannes Taminiau	Member	Healthcare Professionals' Representative	No interests declared	
Fernando Cabanas	Member	Healthcare Professionals' Representative	No restrictions applicable for the meeting	
Francesca Rocchi	Member	Healthcare Professionals' Representative	No restrictions applicable for the meeting	
Jaroslav Sterba	Member	Patients' Organisation Representative	No interests declared	
Dimitrios	Member	Patients'	No interests declared	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Athanasiou		Organisation Representative		
Tomasz Grybek	Alternate	Patients' Organisation Representative	No interests declared	
Michal Odermarsky	Alternate	Patients' Organisation Representative	No restrictions applicable for the meeting	
Maria Jesus Fernández Cortizo	Alternate	Spain	No interests declared	
María Estela Moreno Martín	Expert - via telephone*	Spain	No interests declared	
Lutz Wiesner	Expert - via telephone*	Germany	No interests declared	
Ann Marie Totterman	Expert - via telephone*	Finland	No interests declared	
Clemens Mittmann	Expert - via telephone*	Germany	No interests declared	
Flora Musuamba Tshinanu	Expert - via telephone*	Belgium	No restrictions applicable for the meeting	
María Estela Moreno Martín	Expert - via telephone*	Spain	No interests declared	
Meeting run with support from relevant EMA staff				
* Experts were evaluated against the agenda topics or activities they participated in				

13. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Paediatric investigation plan (PIP) (section 2.1 Opinion on PIPs and section 3.1 Discussions on PIPs)
A paediatric investigation plan (PIP) is a development plan aimed at ensuring that the necessary data are obtained through studies in children, when it is safe to do so, to support the authorisation of a medicine for children. Pharmaceutical companies submit proposals for PIPs to the European Medicines Agency's Paediatric Committee (PDCO). This Committee is responsible for agreeing or refusing the plan.

Compliance checks (section 2.2 Opinions on Compliance check, section 3.2 Discussions on Compliance check)
A compliance check may be necessary before any application for marketing authorisation (even for an adult indication) can be considered valid, if there was no deferral for at least one of the studies agreed in the PIP, or after the due date of initiation or completion of a study/measure. The same applies to some regulatory applications for authorised products, as described above.

Modification of an Agreed Paediatric Investigation Plan (section 2.3 Opinions on Modification of an agreed PIP, section 3.3 Discussions on Modification of an agreed PIP)
The development plan for a medicine can be modified at a later stage as knowledge increases. Modifications can also be made if the applicant encounters such difficulties with the implementation of a PIP, which render it unworkable or no longer appropriate.
In some cases, studies can be deferred until after the studies in adults have been conducted. This ensures that research in children is done only when it is safe and ethical to do so. Even when studies are deferred, the PIP will include details of the paediatric studies and their timelines.

Class waiver (section 6 Discussion on the applicability of class waiver)
As some diseases do not affect children (for example Parkinson's disease), the development of medicines for these diseases should not be performed in children. In these cases, a PIP is not required and it will be waived**.** For more information on the classes of diseases subject to waivers, see class waivers.

Annual reports on deferrals (section 8)
If the medicinal product is approved in the EU, annual reports on the deferred measures in the PIP must be submitted to the Agency.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/